Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
49.90
-0.09 (-0.18%)
At close: Jun 25, 2025, 4:00 PM
49.64
-0.26 (-0.52%)
After-hours: Jun 25, 2025, 7:56 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $203.47M in the quarter ending March 31, 2025, with 20.76% growth. This brings the company's revenue in the last twelve months to $774.00M, up 28.20% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$774.00M
Revenue Growth
+28.20%
P/S Ratio
7.95
Revenue / Employee
$382,977
Employees
2,021
Market Cap
6.18B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GH News
- 15 days ago - Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Business Wire
- 16 days ago - New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - Business Wire
- 22 days ago - Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? - Benzinga
- 22 days ago - FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test - Business Wire
- 23 days ago - National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - Business Wire
- 23 days ago - SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - Business Wire
- 25 days ago - In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Business Wire
- 4 weeks ago - Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Business Wire